Finance

Beta
Lists
DYN:NASDAQ
Dyne Therapeutics, Inc
$20.33
+0.35%
(+0.070) 1D
$20.18
-0.74% (-0.15)
After hours
Closed: Jun 24, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DYN...
Open
$20.38
High
$21.13
Low
$20.27
Mkt. cap
3.36B
Avg. vol.
1.71M
Volume
2.19M
52-wk high
$25.00
52-wk low
$8.06
EPS
-$3.22
Beta
1.09
Shares outstanding
165.31M
No. of employees
263
Open
$20.38
High
$21.13
Low
$20.27
Mkt. cap
3.36B
Avg. vol.
1.71M
Volume
2.19M
52-wk high
$25.00
52-wk low
$8.06
EPS
-$3.22
Beta
1.09
Shares outstanding
165.31M
No. of employees
263
News stories
From sources across the web
About Dyne Therapeutics, Inc
CEO-
Employees263
Founded2017
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websitedyne-tx.com
Analyst Ratings
Based on 9 analysts giving stock ratings to DYN in the past 3 months
Strong Buy
Buy
8
Hold
1
Sell
0
12 month forecast
Based on 9 Wall Street analysts offering 12 month price targets for DYN in the last 3 months.
Highest
Current $20.33
$50.00 (+145.94%)
Average
$39.00 (+91.83%)
Lowest
$24.00 (+18.05%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Francois Brisebois
LifeSci Capital
Buy
Reiterated
$44.00
+116.4%
06/24/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Maintained
$33.00
+62.3%
06/04/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
$47.00
+131.2%
06/03/2026
Ananda Ghosh
H.C. Wainwright
Buy
Maintained
$50.00
+145.9%
05/21/2026
Andreas Argyrides
Oppenheimer
Buy
Reiterated
$40.00
+96.8%
05/21/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$45.00
+121.3%
05/14/2026
William Pickering
Bernstein
Hold
Reiterated
$24.00
+18.1%
05/13/2026
Luca Issi
RBC Capital
Buy
Reiterated
$30.00
+47.6%
05/11/2026
Keay Nakae
Chardan Capital
Buy
Maintained
$38.00
+86.9%
05/11/2026
Tessa Romero
J.P. Morgan
Hold
Maintained
$16.00
-21.3%
03/16/2026
Unknown Analyst
Guggenheim
Buy
Initiated
$50.00
+145.9%
03/08/2026
Last report
May 11, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.73 / -$0.78
+6.65%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
99.24M
97.22M
95.43M
100.89M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
16.56M
16.67M
20.70M
24.39M
Operating expense
115.79M
113.89M
116.13M
125.28M
Total operating expenses
115.79M
113.89M
116.13M
125.28M
Operating income
-115.79M
-113.89M
-116.13M
-125.28M
Other non operating income
3.00K
-
-
-233.00K
EBT including unusual items
-110.86M
-108.04M
-111.96M
-120.85M
EBT excluding unusual items
-110.86M
-108.04M
-111.97M
-120.85M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-110.86M
-108.04M
-111.96M
-120.85M
Net profit margin
-
-
-
-
Earnings per share
-0.97
-0.76
-0.73
-0.73
Interest and investment income
6.62M
8.48M
7.66M
8.76M
Interest expense
-94.00K
-2.90M
-3.19M
-4.20M
Net interest expenses
6.53M
5.57M
4.46M
4.56M
Depreciation and amortization charges
-
-
-
-
EBITDA
-115.29M
-113.37M
-115.61M
-124.73M
Gain or loss from assets sale
-
-
-
30.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer